FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026258433> ?p ?o ?g. }

• W2026258433 endingPage "1193" @default.
• W2026258433 startingPage "1187" @default.
• W2026258433 abstract "BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients.In this 12-week placebo-controlled multicentre study, we randomly assigned 35 patients with active ankylosing spondylitis to intravenous infliximab (5 mg/kg) and 35 to placebo at weeks 0, 2, and 6. One patient in the infliximab group was withdrawn from the study. Our primary outcome was regression of disease activity of at least 50%. To assess response, we used validated clinical criteria from the ankylosing spondylitis assessment working group, including disease activity (BASDAI), functional indices (BASFI), metrology (BASMI), and quality of life (short form 36). Analyses were done by intention to treat.18 (53%) of 34 patients on infliximab had a regression of disease activity at week 12 of at least 50% compared with three (9%) of 35 on placebo (difference 44% [95% CI 23-61], p<0.0001). Function and quality of life also improved significantly on infliximab but not on placebo (p<0.0001 and p<0.0001, respectively). Treatment with infliximab was generally well tolerated, but three patients had to stop treatment because of systemic tuberculosis, allergic granulomatosis of the lung, or mild leucopenia.Our results show that treatment with infliximab is effective in patients with active ankylosing spondylitis. Since there are some potentially serious adverse effects, we recommend that this treatment mainly be used in co-operation with rheumatological centres." @default.
• W2026258433 created "2016-06-24" @default.
• W2026258433 creator A5003040843 @default.
• W2026258433 creator A5011323027 @default.
• W2026258433 creator A5011554462 @default.
• W2026258433 creator A5012794658 @default.
• W2026258433 creator A5019710723 @default.
• W2026258433 creator A5032375376 @default.
• W2026258433 creator A5044290696 @default.
• W2026258433 creator A5052284888 @default.
• W2026258433 creator A5054732492 @default.
• W2026258433 creator A5060526475 @default.
• W2026258433 creator A5064493310 @default.
• W2026258433 creator A5080104419 @default.
• W2026258433 creator A5081920237 @default.
• W2026258433 creator A5085745432 @default.
• W2026258433 date "2002-04-01" @default.
• W2026258433 modified "2023-09-30" @default.
• W2026258433 title "Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial" @default.
• W2026258433 cites W1966756689 @default.
• W2026258433 cites W1974903457 @default.
• W2026258433 cites W1975545950 @default.
• W2026258433 cites W1978655912 @default.
• W2026258433 cites W1979377048 @default.
• W2026258433 cites W1985763670 @default.
• W2026258433 cites W1997192647 @default.
• W2026258433 cites W2020869366 @default.
• W2026258433 cites W2022917163 @default.
• W2026258433 cites W2027454708 @default.
• W2026258433 cites W2030187620 @default.
• W2026258433 cites W2038535814 @default.
• W2026258433 cites W2041327354 @default.
• W2026258433 cites W2065029052 @default.
• W2026258433 cites W2076276957 @default.
• W2026258433 cites W2091239293 @default.
• W2026258433 cites W2091452114 @default.
• W2026258433 cites W2112340015 @default.
• W2026258433 cites W2127711040 @default.
• W2026258433 cites W2143510315 @default.
• W2026258433 cites W2167467847 @default.
• W2026258433 cites W2168698481 @default.
• W2026258433 cites W2319957449 @default.
• W2026258433 cites W4292806894 @default.
• W2026258433 doi "https://doi.org/10.1016/s0140-6736(02)08215-6" @default.
• W2026258433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11955536" @default.
• W2026258433 hasPublicationYear "2002" @default.
• W2026258433 type Work @default.
• W2026258433 sameAs 2026258433 @default.
• W2026258433 citedByCount "1166" @default.
• W2026258433 countsByYear W20262584332012 @default.
• W2026258433 countsByYear W20262584332013 @default.
• W2026258433 countsByYear W20262584332014 @default.
• W2026258433 countsByYear W20262584332015 @default.
• W2026258433 countsByYear W20262584332016 @default.
• W2026258433 countsByYear W20262584332017 @default.
• W2026258433 countsByYear W20262584332018 @default.
• W2026258433 countsByYear W20262584332019 @default.
• W2026258433 countsByYear W20262584332020 @default.
• W2026258433 countsByYear W20262584332021 @default.
• W2026258433 countsByYear W20262584332022 @default.
• W2026258433 countsByYear W20262584332023 @default.
• W2026258433 crossrefType "journal-article" @default.
• W2026258433 hasAuthorship W2026258433A5003040843 @default.
• W2026258433 hasAuthorship W2026258433A5011323027 @default.
• W2026258433 hasAuthorship W2026258433A5011554462 @default.
• W2026258433 hasAuthorship W2026258433A5012794658 @default.
• W2026258433 hasAuthorship W2026258433A5019710723 @default.
• W2026258433 hasAuthorship W2026258433A5032375376 @default.
• W2026258433 hasAuthorship W2026258433A5044290696 @default.
• W2026258433 hasAuthorship W2026258433A5052284888 @default.
• W2026258433 hasAuthorship W2026258433A5054732492 @default.
• W2026258433 hasAuthorship W2026258433A5060526475 @default.
• W2026258433 hasAuthorship W2026258433A5064493310 @default.
• W2026258433 hasAuthorship W2026258433A5080104419 @default.
• W2026258433 hasAuthorship W2026258433A5081920237 @default.
• W2026258433 hasAuthorship W2026258433A5085745432 @default.
• W2026258433 hasConcept C126322002 @default.
• W2026258433 hasConcept C141071460 @default.
• W2026258433 hasConcept C142724271 @default.
• W2026258433 hasConcept C17991360 @default.
• W2026258433 hasConcept C204787440 @default.
• W2026258433 hasConcept C27081682 @default.
• W2026258433 hasConcept C2776260265 @default.
• W2026258433 hasConcept C2777138892 @default.
• W2026258433 hasConcept C2777402515 @default.
• W2026258433 hasConcept C2777453003 @default.
• W2026258433 hasConcept C2779134260 @default.
• W2026258433 hasConcept C2779650986 @default.
• W2026258433 hasConcept C2780415856 @default.
• W2026258433 hasConcept C71924100 @default.
• W2026258433 hasConceptScore W2026258433C126322002 @default.
• W2026258433 hasConceptScore W2026258433C141071460 @default.
• W2026258433 hasConceptScore W2026258433C142724271 @default.
• W2026258433 hasConceptScore W2026258433C17991360 @default.
• W2026258433 hasConceptScore W2026258433C204787440 @default.
• W2026258433 hasConceptScore W2026258433C27081682 @default.
• W2026258433 hasConceptScore W2026258433C2776260265 @default.
• W2026258433 hasConceptScore W2026258433C2777138892 @default.

• next